Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia

Karen Seiter, Aleksandra Mamorska-DygaDepartment of Medicine, Division of Hematology/Oncology, New York Medical College, Valhalla, NY, USA Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Fludarabine-based regimens demonstrate higher response r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seiter K, Mamorska-Dyga A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Chronic Lymphocytic Leukemia Obinutuzumab Chlorambucil Elderly Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/f9c0038421104ec9ab2fd7c9d90e81f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9c0038421104ec9ab2fd7c9d90e81f4
record_format	dspace
spelling	oai:doaj.org-article:f9c0038421104ec9ab2fd7c9d90e81f42021-12-02T06:35:44ZObinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia1178-1998https://doaj.org/article/f9c0038421104ec9ab2fd7c9d90e81f42015-06-01T00:00:00Zhttps://www.dovepress.com/obinutuzumab-treatment-in-the-elderly-patient-with-chronic-lymphocytic-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Karen Seiter, Aleksandra Mamorska-DygaDepartment of Medicine, Division of Hematology/Oncology, New York Medical College, Valhalla, NY, USA Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Fludarabine-based regimens demonstrate higher response rates in younger patients but have a significant risk of infection and are thus poorly tolerated by older, frail patients. Anti-CD20 monoclonal antibodies have added to the efficacy of chemotherapy in CLL. Obinutuzumab is a potent Type II anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular toxicity and direct cell death compared with rituximab. In Phase I studies, infusion reactions and neutropenia were the predominant toxicities. Phase II studies demonstrated efficacy both as a single agent and in combination with chemotherapy in patients with CLL. The CLL11 trial was a Phase III randomized trial of chlorambucil alone or with either obinutuzumab or rituximab in elderly, unfit patients. Progression-free survival (the primary end point) was 26.7 months for patients receiving obinutuzumab plus chlorambucil versus 16.3 months for those receiving rituximab plus chlorambucil and 11.1 months for those receiving chlorambucil alone (P<0.001). Overall survival was improved for patients receiving obinutuzumab plus chlorambucil versus chlorambucil alone (P=0.002). This trial led to the US Food and Drug Administration (FDA) approval of obinutuzumab in this patient population.Keywords: chronic lymphocytic leukemia, obinutuzumab, chlorambucil, elderlySeiter KMamorska-Dyga ADove Medical PressarticleChronic Lymphocytic LeukemiaObinutuzumabChlorambucilElderlyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 10, Pp 951-961 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Chronic Lymphocytic Leukemia Obinutuzumab Chlorambucil Elderly Geriatrics RC952-954.6
spellingShingle	Chronic Lymphocytic Leukemia Obinutuzumab Chlorambucil Elderly Geriatrics RC952-954.6 Seiter K Mamorska-Dyga A Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
description	Karen Seiter, Aleksandra Mamorska-DygaDepartment of Medicine, Division of Hematology/Oncology, New York Medical College, Valhalla, NY, USA Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries. Fludarabine-based regimens demonstrate higher response rates in younger patients but have a significant risk of infection and are thus poorly tolerated by older, frail patients. Anti-CD20 monoclonal antibodies have added to the efficacy of chemotherapy in CLL. Obinutuzumab is a potent Type II anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular toxicity and direct cell death compared with rituximab. In Phase I studies, infusion reactions and neutropenia were the predominant toxicities. Phase II studies demonstrated efficacy both as a single agent and in combination with chemotherapy in patients with CLL. The CLL11 trial was a Phase III randomized trial of chlorambucil alone or with either obinutuzumab or rituximab in elderly, unfit patients. Progression-free survival (the primary end point) was 26.7 months for patients receiving obinutuzumab plus chlorambucil versus 16.3 months for those receiving rituximab plus chlorambucil and 11.1 months for those receiving chlorambucil alone (P<0.001). Overall survival was improved for patients receiving obinutuzumab plus chlorambucil versus chlorambucil alone (P=0.002). This trial led to the US Food and Drug Administration (FDA) approval of obinutuzumab in this patient population.Keywords: chronic lymphocytic leukemia, obinutuzumab, chlorambucil, elderly
format	article
author	Seiter K Mamorska-Dyga A
author_facet	Seiter K Mamorska-Dyga A
author_sort	Seiter K
title	Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
title_short	Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
title_full	Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
title_fullStr	Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
title_full_unstemmed	Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
title_sort	obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/f9c0038421104ec9ab2fd7c9d90e81f4
work_keys_str_mv	AT seiterk obinutuzumabtreatmentintheelderlypatientwithchroniclymphocyticleukemia AT mamorskadygaa obinutuzumabtreatmentintheelderlypatientwithchroniclymphocyticleukemia
_version_	1718399850688544768

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia

Ejemplares similares